With EULAR in full swing in Madrid, much of the focus, as in other therapeutic areas, has been on the use of biomarkers to guide personalized treatment options.
It’s an area that particularly concerns Brian Gavin, vice president of the Orencia (abatacept) program at New York-based major Bristol-Myers Squibb (NYSE: BMY).
Dr Gavin is also focused on getting to patients early in order to disrupt the progression of rheumatoid arthritis, a life-changing disease which, if left untreated, leads to functional disability, pain and premature mortality.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze